Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Valneva Austria GmbH Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

NCT01047839
View directory record Official record
Conditions
Encephalitis
Interventions
IC51
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
2 Months to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 1, 2026, 10:08 PM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

NCT04546724
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
VLA1553, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
4,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
44
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

NCT06334393
View directory record Official record
Conditions
Zika, Zika Virus Infection
Interventions
VLA1601, CpG 1018®, 3M-052-AF
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

NCT03576183
View directory record Official record
Conditions
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Interventions
VLA1701, Placebo, Challenge Strain
Biological · Other
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

NCT02316470
View directory record Official record
Conditions
Clostridium Difficile
Interventions
VLA84, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
Huntsville, Alabama • Chula Vista, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

NCT05477524
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
5 Years and older
Enrollment
12,546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
82
States / cities
Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

NCT01246479
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Blood draw, IC51 has given in the parent study IC51-322
Procedure · Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
9 Months to 20 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

NCT03425149
View directory record Official record
Conditions
Zika Virus, Zika Virus Infection
Interventions
VLA1601, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

NCT03010228
View directory record Official record
Conditions
Lyme Borreliosis, Nervous System
Interventions
VLA15 with Alum, VLA15 without Alum
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 39 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Mesa, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

NCT03970733
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

NCT04801420
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
19
States / cities
Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

NCT04786444
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
Biological Vaccine VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Coral Gables, Florida • Fort Myers, Florida • Ponte Vedra, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 1, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

NCT04838444
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Phoenix, Arizona • Hallandale, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

NCT03382964
View directory record Official record
Conditions
Chikungunya
Interventions
VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Huntsville, Alabama • Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 1, 2026, 10:08 PM EDT